Naglazyme: profile and news

International Approvals: Tamiflu, Macugen, Naglazyme Feb 13, 2006
On January 30, the European Commission approved galsulfase 1-mg/mL injection (Naglazyme, made by Biomarin Pharmaceutical, Inc) for long-term enzyme-replacement ... - Medscape (subscription)

BioMarin Announces Fourth Quarter and Year-End 2005 Financial ... Feb 23, 2006
During this time, we achieved key company milestones, including the approval of Naglazyme in both the United States and Europe, the completion of the double ... - PR Newswire (press release),

BioMarin to Present at Cowen & Co. 26th Annual Health Care ... Feb 27, 2006
Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin ... - Yahoo! News (press release)

BioMarin Receives Marketing Approval for Naglazyme in European ... Jan 30, 2006
...(Nasdaq and SWX: BMRN) announced today that the European Commission has granted marketing authorization for Naglazyme(TM) (galsulfase), the first specific ... - MSN Money

BioMarin drug Naglazyme gets EU approval Jan 30, 2006
...(BMRN.O: Quote, Profile, Research) on Monday said European regulators approved its drug Naglazyme to treat a rare genetic disease with orphan drug status ... - Reuters

BioMarin Receives Marketing Approval for Naglazyme in European ... Jan 30, 2006
2006 Revenue Guidance for Naglazyme and Aldurazyme Provided Conference Call to be Held Today at 5:00 pm ET (23:00 CET) NOVATO, Calif., Jan. ... - PR Newswire (press release),

BioMarin Receives Marketing Approval for Naglazyme in European ... Jan 30, 2006
...announced today that the European Commission has granted marketing authorization for Naglazyme(TM) (galsulfase), the first specific treatment approved in the ... - PharmaLive.com (press release),

BioMarin Receives Marketing Approval for Naglazyme in European ... Jan 31, 2006
...announced yesterday that the European Commission has granted marketing authorization for Naglazyme(TM) (galsulfase), the first specific treatment approved in ... - DG News

BioMarin Establishes Commercial Operations in Europe Jan 10, 2006
...announced today that it has established commercial operations in Europe in anticipation of receiving European marketing approval for Naglazyme(TM) (galsulfase ... - PR Newswire (press release),

European regulators OK BioMarin drug Jan 30, 2006
The company also predicted 2006 sales of the Naglazyme drug will range from $28 million to $32 million and forecast year-end sales of its Aldurazyme therapy ... - BusinessWeek

(PRN) - Chesapeake Energy Corporation Announces Private Offering ... Jan 30, 2006
...(PRN) - Myogen to Present at the NASDAQ US Small Cap Conference ... [+. PRN) - BioMarin Receives Marketing Approval for Naglazyme in European Union ... [+. ... - Bolsamania.com,

BioMarin Receives FDA Fast Track Designation for Phenoptin for PKU Jan 25, 2006
Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin ... - PR Newswire (press release),

Schaeffer's Top and Bottom Ranked Stocks (BMRN, ELNK, LGF) Jan 12, 2006
...inhabitants. The firm's Naglazyme medication combats Maroteaux-Lamy syndrome, from which only about 1,100 sufferers exist worldwide. ... - Schaeffers Research,

Biotechnology Industry Ends 2005 with Breakthrough Product ... Jan 18, 2006
Some orphan drugs approved are: BioMarin's Naglazyme, an enzyme replacement therapy for mucopolysaccharidosis VI; Tercica Inc.'s Increlex, long-term treatment ... - Yahoo! News (press release)

BioMarin to Host Research and Development Day on Tuesday, December ... Nov 22, 2005
Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin ... - PR Newswire (press release),

BioMarin Announces Positive Opinion for Naglazyme From European ... Sep 15, 2005
European Medicines Evaluation Agency (EMEA), has issued a positive opinion on the company's Marketing Authorization Application for Naglazyme(TM) (galsulfase ... - PR Newswire (press release),

BioMarin's Naglazyme gets positive opinion from CHMP for EU ... Sep 15, 2005
...from the EU's Committee for Medicinal Products for Human Use (CHMP) recommending that the EU Commission grant marketing authorisation for Naglazyme, a therapy ... - ForexTV.com,

Committee for Medicinal Products for Human Use Summary of Opinion ... Sep 16, 2005
...recommending to grant a marketing authorisation for the medicinal product Naglazyme, 1 mg/ml, concentrate for solution for infusion intended for long-term ... - PharmaLive.com (press release),

BioMarin to Present at the 2005 UBS Global Life Science Conference Sep 20, 2005
Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin ... - PharmaLive.com (press release),

(PRN) - Hollinger International Announces Intention To Announce ... Sep 15, 2005
...an A ... [+. PRN) - BioMarin Announces Positive Opinion for Naglazyme From European Regulatory Authority ... [+. PRN) - MAXIM ... - Bolsamania.com,

FDA Approvals: Naglazyme, Trizivir, Levaquin Aug 11, 2005
On May 31, the FDA approved galsulfase 1-mg/mL injection (Naglazyme, made by Biomarin Pharmaceutical, Inc.) to improve walking and stair-climbing capacity in ... - Medscape (subscription)

BioMarin to Present at the NewsMakers in the Biotech Industry ... Sep 7, 2005
Approved products include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin ... - PR Newswire (press release),

Drug gives hope in enzyme disorder Aug 25, 2005
...kill her. The enzyme replacement therapy, called Naglazyme, was just approved this summer by the Food and Drug Administration. It's ... - Fort Lauderdale Sun Sentinel,

BioMarin's Follows Genzyme's Playbook Aug 23, 2005
...more. In June, BioMarin received US Food and Drug Administration approval for its third drug, Naglazyme, to treat MPS VI. Despite ... - Forbes

Briarcliff Manor girl gets new treatment Aug 10, 2005
...arms over her head. The treatment Alena received yesterday, called Naglazyme, is an enzyme replacement therapy. It was infused over ... - The Journal News.com,